NovaBay Pharmaceuticals, Inc.

NBY · New York Stock Exchange Arca · USD

1,4699USD

−0,4801 (−24,62 %)Stand 22. Mai, 16:37

Vortag 1,95

Kennzahlen

Eröffnung
1,4699
Vortag
1,95
Tagesspanne
1,4699 – 1,4699
52 Wochen
1,11 – 99,75
Volumen
86.826
Ø Volumen
552.072
Börsenwert
39,14 Mio. $
KGV
–
Gewinn je Aktie (TTM)
–
Dividendenrendite
–
Beta
0,2
Nächste Zahlen
–

Finanzen

Gerade nicht verfügbar.

Bewertung

Gerade nicht verfügbar.

Analysten

Einstufungen

Gerade nicht verfügbar.

Kursziel

Gerade nicht verfügbar.

Quartalszahlen

Gerade nicht verfügbar.

Dividenden und Splits

Gerade nicht verfügbar.

Aktiensplits

Gerade nicht verfügbar.

Eigentümer

Institutionen

Gerade nicht verfügbar.

Insider-Geschäfte

Gerade nicht verfügbar.

Vergleichbare Unternehmen

Gerade nicht verfügbar.

Über das Unternehmen

NovaBay Pharmaceuticals, Inc. (NBY) is a pharmaceutical company that specializes in developing and globally distributing products for eyecare and dermatology. Its product portfolio includes Avenova, an advanced solution designed for cleaning the delicate skin around the eye, such as the eyelids, by removing foreign substances, microorganisms, and debris. The company also offers wound management solutions under its NeutroPhase and PhaseOne brands. Furthermore, NovaBay provides a variety of dermatological treatments through its DERMAdoctor brand, addressing diverse skin concerns. These include conditions like keratosis pilaris, rosacea, and eczema, as well as anti-aging formulations, SPF protection, remedies for hyperhidrosis (excessive sweating), solutions for unwanted hair, and acne treatments. The company distributes its products through a multi-channel approach, utilizing traditional retailers, digital beauty platforms, various distributors, and its own online sales channels. Founded in 2000, the company was initially known as NovaCal Pharmaceuticals, Inc., before officially adopting the name NovaBay Pharmaceuticals, Inc. in February 2007. Its corporate headquarters are located in Emeryville, California.

CEO
Michael Kazley
Mitarbeitende
13
Hauptsitz
EmeryVille, CA, US
Sektor
Healthcare
Branche
Biotechnology
Börsengang
26. Okt. 2007

Nachrichten

Gerade nicht verfügbar.

Kurse mindestens 15 Minuten verzögert. Daten: Financial Modeling Prep. Keine Anlageberatung.